Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01339
|
|||||
| Drug Name |
Gimatecan
|
|||||
| Synonyms |
LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Brain and central nervous system tumors [ICD11: 2A00] | Phase 1/2 | [1] | |||
| Structure |
|
![]() |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H25N3O5
|
|||||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)C=NOC(C)(C)C)O
|
|||||
| InChI |
InChI=1S/C25H25N3O5/c1-5-25(31)18-10-20-21-16(12-28(20)22(29)17(18)13-32-23(25)30)15(11-26-33-24(2,3)4)14-8-6-7-9-19(14)27-21/h6-11,31H,5,12-13H2,1-4H3/b26-11+/t25-/m0/s1
|
|||||
| InChIKey |
UIVFUQKYVFCEKJ-OPTOVBNMSA-N
|
|||||
| CAS Number |
CAS 292618-32-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 447.5 | Topological Polar Surface Area | 101 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00087061) Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma | |||||
| 2 | Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9. | |||||
| 3 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
